• Explore /
  • Poster
  • / Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Abstract Poster

Authors

null

Franck Pages

INSERM, Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Paris, France

Franck Pages , Thierry Andre , Julien Taieb , Dewi Vernerey , Julie Henriques , Christophe Borg , Florence Marliot , Rim Ben Jannet , Christophe Louvet , Laurent Mineur , Jaafar Bennouna , Jérôme Desrame , Roger Faroux , Alex Duval , Pierre Laurent-Puig , Magali Svrcek , Fabienne Hermitte , Aurelie Catteau , Jerome Galon , Jean-François Emile

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03422601

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3513)

DOI

10.1200/JCO.2019.37.15_suppl.3513

Abstract #

3513

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Franck Pages

First Author: David Lau

First Author: Aziz Zaanan

First Author: Frank A. Sinicrope